Piper Jaffray Maintains Overweight on Aerie Pharmaceuticals, Lowers Price Target to $48

Piper Jaffray maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $53 to $48.

Benzinga · 11/07/2019 17:04

Piper Jaffray maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $53 to $48.